Cancers

Journal Browser

► Journal Browser

Image-Assisted High-Precision Radiation Oncology

Share This Special Issue

Special Issue Editor

Dr. He C. Wang

E-Mail Website
Guest Editor

Radiation Physics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Interests: radiation oncology

Special Issue Information

Dear Colleagues,

Radiation oncology has achieved remarkable advancements in cancer care, with image-assisted techniques emerging as a cornerstone for achieving effective and high-precision treatment. By integrating medical imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), four-dimensional CT (4DCT), dual-energy CT (DECT), and optical surface imaging, radiation therapy can be tailored to the unique anatomical and physiological characteristics of each patient. These technologies enable accurate tumor localization and delineation, provide advanced image guidance through precise positioning and real-time motion tracking, and facilitate adaptive dose delivery, therefore minimizing damage to surrounding healthy tissues while enhancing treatment efficacy. Furthermore, the addition of artificial intelligence (AI) techniques and radiomics promotes efficient and standardized radiotherapy, while also offering predictive insights into treatment optimization and tumor response. As the field progresses, image-assisted high-precision radiation therapy will be poised to improve survival rates and reduce treatment-related complications, marking a significant leap toward personalized oncology care.

Dr. He C. Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.

Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.

Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.

External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.

Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

10 pages, 733 KB

Open AccessArticle

Generalization of the Conformity Index for Multi-Target Radiotherapy Plans

by Yong Sang, Jun Dang, Jianan Wu, Yanling Wu, Enzhuo Quan and Jianrong Dai

Cancers 2026, 18(3), 426; https://doi.org/10.3390/cancers18030426 - 28 Jan 2026

Viewed by 560

Abstract

Background and Purpose: Based on the distortion of the current conformity index (CI) formula in handling multi-target plans, the

V_{T V}

parameter in the current CI formula has been redefined to more accurately calculate the CI value of multi-target plans, providing a [...] Read more.

Background and Purpose: Based on the distortion of the current conformity index (CI) formula in handling multi-target plans, the

V_{T V}

parameter in the current CI formula has been redefined to more accurately calculate the CI value of multi-target plans, providing a reference for clinical applications. Methods and Materials: Considering the limitations of the current

V_{T V}

calculation formula in CI proposed by van’t Riet and Paddick, a new

V_{T V}

has been defined to better reflect the true conformity of the target volume in multi-target planning. We selected 15 breast cancer (BC) plans with PTVsc and PTVcw as the target volumes, and 15 nasopharyngeal carcinoma (NPC) plans with PTVp, PTVn, PTVrpn, PTV1, and PTV2 as target volumes.

V_{T V}^{n e w}

and

C I_{n e w}

were calculated using the proposed formulas, while

V_{T V}^{o l d}

and

C I_{o l d}

were calculated using traditional formulas based on van’t Riet and Paddick. A paired, two-tailed Wilcoxon signed-rank test was conducted to compare

V_{T V}^{n e w}

with

V_{T V}^{o l d}

, and

C I_{n e w}

with

C I_{o l d}

across all target volumes. Pearson’s correlation analysis was performed between

C I_{n e w}

and

C I_{o l d}

. Results: For BC, the

V_{T V}

values calculated by the two methods for PTVsc and PTVcw showed statistically significant differences; the values calculated in this study were significantly lower than those calculated by van’t Riet and Paddick (p < 0.05). Consequently, the

C I_{n e w}

values for BC were significantly higher than

C I_{o l d}

. These results were consistent with those for PTVp, PTVn, PTVrpn, and PTV2 in NPC. For PTV1 in NPC, the results calculated by the two formulas were identical. Conclusions: The new

V_{T V}

calculation formula eliminates the influence of dose spillage from adjacent targets, retaining only the prescription dose range of the specific target under analysis. This makes the calculated CI more reflective of true conformity compared to traditional formulas. We recommend using the proposed formula to calculate CI values for multi-target plans such as those for BC and NPC. Full article

(This article belongs to the Special Issue Image-Assisted High-Precision Radiation Oncology)

► Show Figures

Figure 1

20 pages, 2956 KB

Open AccessArticle

Tumor Microenvironment: Insights from Multiparametric MRI in Pancreatic Ductal Adenocarcinoma

by Ramesh Paudyal, James Russell, H. Carl Lekaye, Joseph O. Deasy, John L. Humm, Muhammad Awais, Saad Nadeem, Richard K. G. Do, Eileen M. O’Reilly, Lawrence H. Schwartz and Amita Shukla-Dave

Cancers 2026, 18(2), 273; https://doi.org/10.3390/cancers18020273 - 15 Jan 2026

Viewed by 727

Abstract

Background/Objectives: The tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is characterized by an enriched stroma, hampering the effectiveness of therapy. This co-clinical study aimed to (1) provide insight into early post-treatment changes in the TME using multiparametric magnetic resonance imaging (mpMRI)-derived quantitative imaging biomarkers (QIBs) in a preclinical PDAC model treated with radiotherapy and correlate these QIBs with histology; (2) evaluate the feasibility of obtaining these QIBs in patients with PDAC using clinically approved mpMRI data acquisitions. Methods: Athymic mice (n = 12) at pre- and post-treatment as well as patients with PDAC (n = 11) at pre-treatment underwent mpMRI including diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) data acquisition sequences. DW and DCE data were analyzed using monoexponential and extended Tofts models, respectively. DeepLIIF quantified the total percentage (%) of tumor cells in hematoxylin and eosin (H&E)-stained tissues from athymic mice. Spearman correlation and Wilcoxon signed rank tests were performed for statistical analysis. Results: In the preclinical PDAC model, mean pre- and post-treatment ADC and K^trans values differed significantly (p < 0.01), changing by 20.50% and 20.41%, respectively, and the median total tumor cells quantified by DeepLIIF was 24% (range: 15–53%). Post-treatment ADC values and relative change in v_e (rΔv_e) showed a significant negative correlation with total tumor cells (ρ = −0.77, p < 0.014 for ADC and ρ = −0.77, p = 0.009 for rΔv_e). In patients with PDAC, pre-treatment mean ADC and K^trans values were 1.76 × 10⁻³ (mm²/s) and 0.24 (min⁻¹), respectively. Conclusions: QIBs in both preclinical and clinical settings underscore their potential for future co-clinical research to evaluate emerging drug combinations targeting both tumor and stroma. Full article

(This article belongs to the Special Issue Image-Assisted High-Precision Radiation Oncology)

► Show Figures

Journal Menu

Journal Browser

Image-Assisted High-Precision Radiation Oncology

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (2 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI